Filing Flows › GeneDx Holdings (WGS) › Q4 2025
GeneDx Holdings (WGS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 23, 2026
GeneDx Holdings (WGS) reported revenue of $121M for the fourth quarter 2025 (Q4 2025), +27% from a year earlier and +4% from the quarter before. Operating margin was -11.8%, net loss $17.7M (14.6% of revenue).
GeneDx Holdings, Q4 2025: revenue $121M (+26% year over year), operating margin -11.8%, net loss $17.7M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121M | +4% | +27% |
| Operating profit | −$14.2M | — | -262% |
| Net earnings | −$17.7M | — | -425% |
| Operating cash flow | −$3.1M | -120% | — |
What changed
Revenue was $121.0M in Q4 2025, up 27% year over year and up 4% from the previous quarter. Patients with third-party insurance was the largest line at 84% of revenue.
Gross margin was 69.6%, up 0.4 points from Q4 2024. Operating costs exceeded revenue by $14.2M, an operating margin of -11.8%. Operating expenses grew 72% against revenue growth of 27%. The fastest-growing cost line was Research & development (+112%). The quarter ended with a net loss of $17.7M, wider than the previous quarter's $7.6M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $6.9M of depreciation and amortization and $9.8M of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $4.3M exceeded it, leaving free cash flow of −$7.4M.
Questions
What was GeneDx Holdings' revenue in the fourth quarter 2025?
GeneDx Holdings (WGS) reported revenue of $121M for the fourth quarter 2025 (Q4 2025), +27% from a year earlier and +4% from the quarter before.
Was GeneDx Holdings profitable in the fourth quarter 2025?
Operating loss was $14.2M (-11.8% of revenue) and net loss $17.7M.
Source: GeneDx Holdings 10-K on SEC EDGAR.